Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis
详细信息 查看全文
- 作者：In Gyu Hwang (1)
Hong Suk Song (2)
Myung Ah Lee (3)
Eun Mi Nam (4)
Joohan Lim (5)
Kyung Hee Lee (6)
Kyu Taek Lee (7)
Dae Young Zang (8)
Joung-Soon Jang (1) (9) - 关键词：Biliary tract cancer ; Efficacy ; Gemcitabine ; Platinum ; Retrospective analysis
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：74
- 期：6
- 页码：1291-1296
- 全文大小：266 KB
- 参考文献：1. Aljiffry M, Walsh MJ, Molinari M (2009) Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-009. WJG 15:4240-262 CrossRef
2. Anderson CD, Pinson CW, Berlin J, Chari RS (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9:43-7 CrossRef
3. Blechacz B, Gores GJ (2008) Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48:308-21 CrossRef
4. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, Gruenberger T (2010) Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 11:1142-148 CrossRef
5. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY (2012) Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13:181-88 CrossRef
6. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469-74 CrossRef
7. Sasaki T, Isayama H, Nakai Y, Koike K (2013) Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med 28:515-24 CrossRef
8. Shoda J, Ishige K, Sugiyama H, Kawamoto T (2012) Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options. J Hepato Biliary Pancreat Sci 19:342-53 CrossRef
9. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273-281 CrossRef
10. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study: the UK ABC-01 study. Br J Cancer 101:621-27 CrossRef
11. Yang R, Wang B, Chen YJ, Li HB, Hu JB, Zou SQ (2013) Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis. Anticancer Drugs 24:871-77 CrossRef - 作者单位：In Gyu Hwang (1)
Hong Suk Song (2)
Myung Ah Lee (3)
Eun Mi Nam (4)
Joohan Lim (5)
Kyung Hee Lee (6)
Kyu Taek Lee (7)
Dae Young Zang (8)
Joung-Soon Jang (1) (9)
1. Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 156-756, Korea
2. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, 705-701, Korea
3. Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University, Seoul, 137-701, Korea
4. Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul, 158-710, Korea
5. Department of Internal Medicine, Inha University College of Medicine, Incheon, 400-711, Korea
6. Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, 705-717, Korea
7. Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, 330-721, Korea
8. Department of Internal Medicine, Hallym University College of Medicine, Anyang, 431-796, Korea
9. Division of Hematology/Oncology, Chung-Ang University Hospital, 224 Heukseok-dong, Dongjak-gu, Seoul, 156-755, Korea - ISSN：1432-0843
文摘
Purpose ABC-02 trial of gemcitabine plus cisplatin combination showed prolongation of overall survival in biliary tract cancer (BTC) patients. In this multicenter retrospective study, we evaluated the treatment outcome of gemcitabine combined with platinum (GP) compared to that of gemcitabine (G) alone in Korean BTC patients. Methods One hundred and fifty-one patients with histologically confirmed biliary tract adenocarcinoma were enrolled at nine institutions between July 2003 and May 2011, including 100 treated with GP and 51 treated with G. Results With a median follow-up of 7.7?months (range 0.4-8.3?months), the median overall survival (OS) was 12.4?months [95?% confidence interval (CI) 9.4-5.6?months] of the G group, which was not significantly different for the median OS of 11.0?months (95?% CI 9.7-2.3?months) of the GP group (p?=?0.599). The median progression-free survival (PFS) was 3.9?months (95?% CI 0.8-.0?months) in the G group and 3.3?months (95?% CI 2.6-.0?months) in the GP group (p?=?0.504). Overall response rates (ORR) were 18.8?% in G group and 23.9?% in GP group (p?=?0.485). Conclusions There was no significant difference in ORR, PFS, or OS for patients between the G group and the GP group, which was different from the ABC-02 trial. Therefore, gemcitabine monotherapy and GP combination are both effective regimens for Korean BTC patients.